Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.75 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584719 | 0.88 | ADORA2A (0.58) | ADORA2AADORA1BRD4ADORA2BCREBBP | |
| SCHEMBL4584418 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1BRD4ADORA2BADORA3 | |
| SCHEMBL29443963 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1BRD4ADORA2BADORA3 | |
| SCHEMBL29907659 | 0.83 | ADORA2A (0.56) | ADORA2AADORA1BRD4ADORA2BCREBBP | |
| SCHEMBL12077150 | 0.81 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL28463384 | 0.79 | ADORA2A (0.55) | ADORA2AADORA1BRD4ADORA2BADORA3 | |
| SCHEMBL4584602 | 0.79 | ADORA2A (0.48) | ADORA2AADORA1BRD4ADORA2BCREBBP | |
| SCHEMBL4584321 | 0.79 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3DYRK1A | |
| SCHEMBL4584161 | 0.77 | ADORA2A (0.84) | ADORA2AADORA1ADORA2BADORA3NPY5R | |
| SCHEMBL21722596 | 0.77 | ADORA2A (0.63) | ADORA2AADORA1BRD4ADORA2BCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112055709-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-7407961-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2008-08-05 | — | — | US | disclosed |
| CN-1871231-A | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC (JP) | 2006-11-29 | — | — | CN | disclosed |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | ADORA2A 1/4885ADORA1 3/4885BRD4 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.